Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.
Borea R, Favero D, Miceli A, Donegani MI, Raffa S, Gandini A, Cremante M, Marini C, Sambuceti G, Zanardi E, Morbelli S, Fornarini G, Rebuzzi SE, Bauckneht M. Borea R, et al. Among authors: fornarini g. Diagnostics (Basel). 2022 Feb 24;12(3):581. doi: 10.3390/diagnostics12030581. Diagnostics (Basel). 2022. PMID: 35328134 Free PMC article. Review.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
Morbelli S, Conzi R, Campus C, Cittadini G, Bossert I, Massollo M, Fornarini G, Calamia I, Marini C, Fiz F, Ghersi C, Derchi LE, Sambuceti G. Morbelli S, et al. Among authors: fornarini g. Cancer Imaging. 2014 Apr 22;14(1):10. doi: 10.1186/1470-7330-14-10. Cancer Imaging. 2014. PMID: 25609564 Free PMC article.
Enzalutamide in Castration-Resistant Prostate Cancer.
Bregni G, Rebuzzi SE, Fornarini G. Bregni G, et al. Among authors: fornarini g. N Engl J Med. 2018 Oct 4;379(14):1380-1. doi: 10.1056/NEJMc1810065. N Engl J Med. 2018. PMID: 30284801 No abstract available.
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizzoni A, Tortora G. Iacovelli R, et al. Among authors: fornarini g. Br J Clin Pharmacol. 2019 Jun;85(6):1283-1289. doi: 10.1111/bcp.13895. Epub 2019 Mar 31. Br J Clin Pharmacol. 2019. PMID: 30740760 Free PMC article.
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, Raffa S, Tomasello L, Vitti M, Cavo A, Catalano F, Mencoboni M, Ceppi M, Marini C, Fornarini G, Boccardo F, Sambuceti G, Morbelli S. Bauckneht M, et al. Among authors: fornarini g. Cancers (Basel). 2019 Dec 20;12(1):31. doi: 10.3390/cancers12010031. Cancers (Basel). 2019. PMID: 31861942 Free PMC article.
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.
Bersanelli M, Buti S, Banna GL, De Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, De Tursi M, Di Marino P, Rossetti S, Rossi E, Tomao S, De Luca E, Sorarù M, Mucciarini C, Atzori F, La Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Di Maio M, Verzoni E, Procopio G, Giannarelli D. Bersanelli M, et al. Among authors: fornarini g. Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180. Immunotherapy. 2020. PMID: 32089035
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study.
Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, Borea R, Raffa S, Damassi A, Ponzano M, Catalano F, Martelli V, Marini C, Boccardo F, Morbelli S, Sambuceti G, Fornarini G. Bauckneht M, et al. Among authors: fornarini g. Cancers (Basel). 2020 Oct 31;12(11):3213. doi: 10.3390/cancers12113213. Cancers (Basel). 2020. PMID: 33142739 Free PMC article.
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi SE, Procopio G, Verzoni E, Bracarda S, Sabbatini R, Baldessari C, Eccher A, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Caliò A, Alongi F, Munari E, Pappagallo G, Iacovelli R, Mosca A, Porta C, Martignoni G, Antonelli A. Brunelli M, et al. Among authors: fornarini g. J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3. J Clin Pathol. 2022. PMID: 33144356
149 results